Browsing Category
Pharma Industry News
4744 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Lupin Limited (NSE: LUPIN) gains on dual U.S. approvals for nasal spray and ophthalmic gel
Lupin Limited gains on U.S. nasal spray launch and FDA approval for ophthalmic gel. Find out how this could reshape its U.S. generics growth strategy.
CyanVac’s nasal COVID-19 vaccine shows strong immune response in U.S. phase 1 clinical trial
CyanVac’s nasal COVID-19 vaccine shows strong mucosal immune response in U.S. phase 1 trial. Larger studies underway to assess full efficacy.
Why amylin is gaining pharma attention in obesity drug development: From amycretin to AZD6234
Discover how Novo Nordisk, AstraZeneca, and others are betting on amylin-based obesity drugs like amycretin and AZD6234 to reshape metabolic care.
Johnson & Johnson seeks EMA approval to expand AKEEGA use for HRR-altered prostate cancer patients
Johnson & Johnson files for EMA approval to extend AKEEGA use in high-risk prostate cancer. Find out how this combo may redefine standard of care.
Clearmind Medicine receives IRB approval in Israel for Phase 1/2a trial targeting alcohol use disorder
Clearmind Medicine wins IRB nod in Israel for its psychedelic-based AUD trial. Find out how this pivotal study could reshape addiction treatment.
How Canada became the preferred launchpad for ophthalmic biosimilars in 2025
With Yesafili’s approval, Canada is emerging as the global launchpad for ophthalmic biosimilars. Explore what’s driving this strategic shift.
JCR Pharmaceuticals completes global Phase III enrollment for JR-141 targeting Hunter syndrome’s neurological symptoms
JCR Pharmaceuticals completes global Phase III enrollment for JR-141, targeting Hunter syndrome CNS symptoms with its BBB-penetrating enzyme therapy.
HanchorBio and Henlius sign $202m licensing deal for HCB101 to expand immuno-oncology access across Asia and MENA
HanchorBio Inc. (7827.TWO), a clinical-stage immunotherapy innovator, has entered a major licensing agreement with Shanghai Henlius Biotech Inc.…
Biocon (NSE: BIOCON) gains EU nod for Denosumab biosimilars Vevzuo and Evfraxy to target bone health market
Biocon Biologics receives EU approval for Denosumab biosimilars Vevzuo and Evfraxy. Find out how this milestone could reshape its European biosimilars strategy.
AN2 Therapeutics reveals 40% 90-day mortality in NIH-backed melioidosis study, advancing epetraborole toward Phase 2 trial
AN2 Therapeutics reports high 90-day mortality in 200-patient NIH-funded melioidosis study, laying groundwork for Phase 2 epetraborole trial in 2025.